drugset
drugset / Trial / NCT05241535

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

NCT05241535 ↗

Phase 1 Completed 29 enrolled Tanabe Pharma America, Inc.
RandomizedCrossoverQuadruple-blindOther

Summary

The purpose of this study is to evaluate the effect of a single oral dose of MT-7117 on the QT/QTc interval in healthy subjects.

Timeline

Start
2022-01-12
Primary completion
2022-02-23
Completion
2022-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Dersimelagon Small molecule — Oral
Subject Moxifloxacin Small molecule — Oral

Indications

No indication recorded.